Navigation Links
MIGENIX Corporate Update and Requisition of Special Meeting
Date:7/8/2008

>

The Company has received from Douglas Johnson (a shareholder holding approximately 5% of MIGENIX's outstanding common shares) a requisition for a special meeting of shareholders for the purpose of replacing a majority of the MIGENIX board of directors. Mr. Johnson has reported that DJohnson Holdings Inc. has beneficial ownership of and/or voting control and direction over a total of 14,042,400 MIGENIX common shares, representing approximately 15% of the total issued and outstanding common shares of Migenix.

The MIGENIX board of directors has appointed a Special Committee of directors in respect of the requisition and related matters, comprising David Scott, Mike Abrams, Alistair Duncan, Steve Gillis and Colin Mallet, all of whom are independent of management. The Company will respond to the requisition of a special meeting as required by law in due course.

Management and the Special Committee believe that Mr. Johnson's actions in seeking to acquire control of the Company has created significant uncertainty and may have a negative impact on current business discussions (e.g. partnering/licensing, government assistance) and other opportunities for funding being pursued by management. This action will also distract management and burden the Company with additional direct and opportunity costs it cannot afford.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (end of Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Exotic Automation & ... the launch of http://www.cng.exoticautomation.com , an ecommerce ... convenient way to purchase genuine OEM replacement CNG, ... , The new website provides owners of fleets ... access to high performance products for their vehicle ...
(Date:5/4/2015)... May 4, 2015 Many of us ... for certain infants with rare, inherited mutations of ... consequences of their impaired immune responses. ... identified an important role for calcium signaling in ... tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... TEL AVIV, Israel , May 4, 2015 /PRNewswire/ ... has filed its annual report on Form 20-F for ... U.S. Securities and Exchange Commission ("SEC"). The annual report ... for the development of antibodies in the area of ... antibodies with superior qualities of high specificity and binding ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
Breaking Biology Technology:Exotic Automation & Supply Launches Ecommerce Website 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... CardioDex announces initial commercial use ... from commercial use of the device on 41 patients at ... and no complications. "We are very excited about these new ... for a major unmet medical need due to the increasing ...
... Pa., May 1, 2012  Discovery Laboratories, Inc. (NASDAQ: ... new pharmacoeconomic analysis demonstrating that the lower rate of ... , when compared with infants treated with Curosurf ® ... leading surfactants, also resulted in a potential hospital cost ...
... 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX ) ... focused on researching, developing, manufacturing and marketing biopharmaceutical products, ... Report on Form 20-F for the fiscal year ended ... Commission on April 30, 2012. The annual report on ...
Cached Biology Technology:New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy 2New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 2Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 4Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 5
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... can produce biodiesel fuel from municipal sewage sludge that is ... conventional diesel refined from petroleum, according to an article in ... is the solid material left behind from the treatment of ... out in the article that demand for biodiesel has led ...
... part of a healthy diet, can increase the levels ... cholesterol, according to an international team of nutritional scientists., ... lowering lipids and lipoproteins, which are a risk factor ... nutrition, Penn State. "This new study shows an additional ...
... the lowly lamprey eel have identified an overlooked nervous ... circuitry in vertebrates such as birds, fishes and mammals. ... , online May 16, and highlighted in the magazine,s ... Illinois at Chicago professor of biological sciences and the ...
Cached Biology News:Pistachios offer multiple benefits 2Pistachios offer multiple benefits 3Parallel brainstem circuit discovery suggests new path in Parkinson's research 2
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: